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Abstract
Age-related macular degeneration (AMD) is the leading cause of blindness in industrialised countries, and thereby a major
individual but also a socio-economic burden. Y chromosome loss in nucleated blood cells has been implicated in age-related
diseases such as Alzheimer disease and was shown to be caused by increasing age, smoking and genetic factors. Mosaic loss
of Y chromosome (mLOY) in peripheral blood was estimated from normalised dosages of genotyping chip data covering the
male-speciﬁc region of the Y chromosome. After quality control, we assessed the association of mLOY on AMD risk in
5772 male cases and 6732 male controls. In controls the prevalence of mLOY increased signiﬁcantly with age, which is
consistent with previous reports. Importantly, mLOY was associated with late-stage AMD with genome-wide signiﬁcance
(OR: 1.332 [95% CI: 1.206; 1.472], P= 1.60e-08), independent of age, the AMD genetic risk score and the ﬁrst two
principle components of ancestry. Additionally conditioning on smoking behaviour had no inﬂuence on the observed
association strength. mLOY was strongest associated in individuals aged between 65 and 75 years. Taken together, mLOY is
signiﬁcantly associated with risk for AMD, independent of known and potential confounding factors.
Introduction
Age-related macular degeneration (AMD) is the most
common cause of blindness in Western societies with age
identiﬁed as the major risk factor for the disease [1]. The
prevalence of AMD rises signiﬁcantly with age; hence
demographic changes towards an increased average life
expectancy are anticipated to cause a growing individual
and socioeconomic burden [2]. Apart from age, environ-
mental/modiﬁable as well as genetic factors have ﬁrmly
been established to be strongly associated with disease risk
[1, 3, 4]. Previous ﬁndings revealed ambiguous results for
an association of gender with AMD and its modulation by
genetic variants [2, 5–7].
The latest genome-wide association study by the Inter-
national AMD Genomics Consortium (IAMDGC) [8–10]
has identiﬁed numerous regions in the genome involved in
AMD pathogenesis. In total, at least 34 regions with cur-
rently more than 52 independent associated lead variants
have been implicated in disease risk, explaining over 50%
of the heritability and more than 30% of disease variance.
Although the majority of the heritability can be explained
by known genetic markers, no cellular pathway besides the
* Bernhard H. F. Weber
bweb@klinik.uni-regensburg.de
1 Institute of Human Genetics, University of Regensburg,
Regensburg, Germany
2 Department of Medical Epidemiology and Biostatistics,
Karolinska Institutet, Stockholm, Sweden
3 Department of Ophthalmology, Radboud University Medical
Center, Nijmegen, The Netherlands
4 Department of Human Genetics, Graduate School of Public
Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
5 Department of Biostatistics, Graduate School of Public Health,
University of Pittsburgh, Pittsburgh, Pennsylvania, USA
6 Clinical and Experimental Sciences, Faculty of Medicine,
University of Southampton, Southampton, UK
7 University College London Institute of Ophthalmology, University
College London, London, UK
Electronic supplementary material The online version of this article
(https://doi.org/10.1038/s41431-018-0238-8) contains supplementary
material, which is available to authorized users.
12
34
56
78
90
()
;,:
12
34
56
78
90
();
,:
complement cascade as part of the innate immune system
was consistently found to be involved in AMD [11].
Mosaic loss of Y chromosome (mLOY) in peripheral
blood is the most common acquired mutation in the process
of normal aging in men, affecting about 1.8% of the genetic
material in the human genome [12]. The prevalence of
mLOY increases with age and can exceed 20% in male
populations older than 80 years [13]. Furthermore, the
occurrence of mLOY is strongly correlated with smoking
behaviour [14]. Current smokers have a more than fourfold
increased risk for mLOY [13], although this effect seems to
be transient as smoking cessation can result in normal
mLOY levels after several years [14, 15].
Recent reports suggested a role of Y chromosome loss in
risk for all-cause mortality and common age-related disease
such as cancer, Alzheimer disease as well as severe ather-
osclerosis [12–20]. Building on such reports, we aimed to
evaluate the contribution of male Y chromosome mosaicism
to the risk for late-stage AMD.
Methods
Description of dataset
Initially, data from 6529 males with late-stage AMD (NV,
GA, or both, GA/NV AMD) and 7815 male control indi-
viduals without fundus changes associated with AMD, all
probands unrelated and of European ancestry were provided
by the IAMDGC [9]. Inclusion and exclusion criteria of the
IAMDGC samples as well as detailed information on oph-
thalmological grading, quality control of genetic and phe-
notypic data as well as imputation are given in detail
elsewhere [9]. The age of patients and controls reported by
the individual studies was usually the date the blood was
drawn and the diagnosis was assessed and/or conﬁrmed in
the recruitment centre or clinic [9]. For the present study,
we excluded 1046 samples, since their DNA was not
retrieved from whole blood. Smoking data were available
for the samples from the Regensburg, EUGENDA (Nij-
megen, the Netherlands and Cologne, Germany), UCLA/
Pittsburgh, Southampton and Cambridge (UK) study
groups, which are part of the IAMDGC dataset. In addition,
smoking status was retrieved from dbGAP for the ARED
study samples [21] (accession: phs000001.v3.p1). In total,
we had smoking information for 2159 samples (ever
smoked/never smoked), 1210 samples (current smoker
status) and 956 samples (pack-years, Table 1). The study
adhered to the tenets of the declaration of Helsinki and is
HIPAA compliant.
Calculation of mLOY
All samples were genotyped on the same genotyping chip
(Illumina HumanCoreExome—Goncalo 15038949). A
continuous variable, the mean of the log R ratio (LRR), was
used to estimate the degree of LOY for each subject and
calculated as the mean LRR value of 608 SNP array probes
that passed quality control (i.e. call rate >95% and not
monomorphic) positioned within the male-speciﬁc region of
the Y chromosome (mLRRY, hg19: 2,694,521 bp—
59,034,049 bp) as described elsewhere [12, 15, 20]. To
exclude samples with excessive noise, we computed the
standard deviation (SD) of all LRR values of 30,789 SNP
array probes on chromosome 1 that passed QC (mLRR1)
and excluded 974 samples with a SD of mLRR1 greater
than 0.28, as suggested by the manufacturer of the array.
This allowed us to assess mLOY in a total of 12,504 indi-
viduals (Table 1). We deﬁned males to have a signiﬁcant
level of mLOY in blood, if their mLRRY value was smaller
than (1) the mean, (2) one or (3) two SDs from the mean
mLRRY in controls. In subsequent analyses, we focused on
Table 1 Baseline characteristics of the study population
Cases Controls All OR [95%CI]a Pa
All ages [N/mLOY] 5772/1145 6732/918 12504/2063 1.332 [1.206; 1.472] 1.60 × 10−08
<65 years [N/mLOY] 538/69 1735/172 2273/241 1.316 [0.969; 1.771] 0.0738
65–70 years [N/mLOY] 675/108 1228/122 1903/230 1.748 [1.321; 2.311] 9.02 × 10−05
70–75 years [N/mLOY] 1131/209 1376/190 2507/399 1.422 [1.147; 1.764] 0.0013
75–80 years [N/mLOY] 1478/268 1191/175 2669/443 1.282 [1.042; 1.580] 0.0195
>80 years [N/mLOY] 1856/482 1161/255 3017/737 1.229 [1.034; 1.465] 0.0201
Ever smoked [%/N] 74.58/1137 63.6/1022 69.38/2159 1.688 [1.397; 2.041] 6.11 × 10−08
Current smoker [%/N] 16.57/519 8.39/691 11.9/1210 2.638 [1.804; 3.886] 6.92 × 10−07
Average pack-years (SD) 27.39 (26.2) 19.81 (23.88) 25.09 (25.75) 1.012 [1.006; 1.018] 2.47 × 10−04
N number of samples, mLOY number of samples with mLOY, OR [95%] odds ratio and 95% conﬁdence interval of association between cases and
controls (mLOY or smoking status), P P value of association between cases and controls, SD standard deviation
aLogistic regression models adjusted for age and the ﬁrst two principal components of ancestry as well as the AMD genetic risk score
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mLOY individuals with mLRRY values smaller than one
SD from the mean mLRRY in controls (2), since the frac-
tion of mLOY individuals in controls was comparable to the
frequency observed in other studies.
Statistical analysis
We ﬁt multivariable linear and logistic regression models
to assess the association of mLRRY and mLOY with late-
stage AMD, respectively, as implemented in R [22]. The
analyses were adjusted for the ﬁrst two principle com-
ponents of ancestry, which were calculated from the
imputed genotypes. In addition, where appropriate we
accounted for the age at blood collection. To exclude
a potential confounding effect of known and strong
AMD associated variants, a genetic risk score (GRS) was
computed for AMD with 52 independent variants from 34
loci, as previously reported [10, 23]. Brieﬂy, we calcu-
lated the sum of risk increasing alleles from 52 AMD
associated variants, weighted by the respective odds ratio
of the variant. To account for smoking status in the sen-
sitivity analysis, we considered individuals who ever
smoked more than one pack-year as smokers and also
adjusted for current smokers as well as the number of
pack-years smoked, if available. We report the odds ratio
of association and the slope of correlation as well as the
respective 95% conﬁdence intervals. The frequency of
mLOY in cases and controls was plotted as a mosaicplot
implemented in R and the mLRRY values across
different age strata are shown as a boxplot, as imple-
mented in R.
Data availability
The genetic data of the IAMDGC can be accessed through
dbGAP (accession: phs001039.v1.p1).
Results
We investigated the association of mLOY in blood cells with
late-stage AMD by using the currently largest collection of
late-stage AMD patients and controls [9]. In total, 12,504
male individuals from 26 studies were included in the ana-
lysis (Table 1). All samples were genotyped simultaneously
on the same chip in the same genotyping centre, resulting in
little heterogeneity of mLOY across studies. Previous
reports indicated a strong correlation between mLOY and
age [12, 13]. As expected, the mean chromosomal dosage of
the Y chromosome, as measured by the average LRR of all
probes on the Y chromosome (mLRRY) decreased (P <
5.15 x 10−64) with age in AMD patients and AMD free
controls (Fig. 1). We also found that current smokers (slope:
−0.02 [95% CI: −0.03; 0.00], P < 0.05), as well as previous
smokers (slope: −0.01 [95% CI: −0.02; 0.00], P < 0.05) had
reduced levels of mLRRY. In addition, the number of pack-
years smoked was inversely correlated to mLRRY (slope per
ten pack-years: −0.002 [95% CI: 0.004; 0.000], P < 0.05).
Fig. 1 Boxplot and mosaicplot of mLOY in AMD patients and controls across different age groups. a The distribution of the mean LRR value
across 608 SNP probes on the Y chromosome (mLRRY) for cases (red) and controls (blue) are depicted as a boxplot across different age strata.
The threshold (T) for mLOY (mLRRY <−0.08) is depicted as a dashed green line. Signiﬁcant differences between the mean mLRRY of cases and
controls, as assessed by multivariate linear regression models adjusted for age, two principal components and AMD genetic risk score are depicted
with asterisks: *P < 0.05; **P < 0.01; ***P < 0.001. b Patients with signiﬁcant loss of Y chromosome (mLOY) were deﬁned by a mLRRY smaller
than one standard deviation from the mean mLRRY values of controls (mLRRY <−0.08). The occurrence of mLOY increased with age in controls
(blue) as well as AMD patients (red). Conversely, cases (orange) as well as controls (light blue) with no mLOY were less frequently observed with
increasing age. Absolute number of cases and the statistical assessment are given in Table 1
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Importantly, we observed a genome-wide signiﬁcant
association of mLRRY (OR per SD increase in mLRRY:
0.867 [95% CI: 0.833; 0.899], P= 8.75 × 10−14) with late-
stage AMD, independent of age, ancestry and known
AMD risk variants (summarised in a single GRS per
person). Next, we deﬁned mLOY as a binary variable in
cases and controls by different agnostic mLRRY thresh-
olds. We found that mLOY was statistically signiﬁcant for
association with AMD, either deﬁned as (1) mLRRY
smaller than the mean mLRRY in controls (OR: 1.249
[95% CI: 1.159; 1.345], P= 4.54 × 10−09), (2) mLRRY
smaller than one SD from the mean of controls (OR: 1.332
[95% CI: 1.206; 1.472], P= 1.60 × 10−08) and (3)
mLRRY smaller than two SDs from the mean of controls
(OR: 1. 711 [95% CI: 1.406; 2.089], P= 1.03 × 10−08).
The observed association was also independent of the
above-mentioned confounders. In subsequent analyses,
we focused on mLOY as deﬁned by mLRRY smaller than
one SD from the mean of mLRRY of controls (2), since
this treshhold resulted in a similar fraction of mLOY in
controls as previously described [15, 16].
When testing the association of mLOY with AMD in
different age groups (Fig. 1), we observed the strongest
association when restricting the analysis to individuals aged
65 to 75. The association strength (i.e. the odds ratio)
decreased in older and younger individuals (Fig. 1). In
addition, we investigated the effect of smoking status on the
association strength with AMD. The observed association
with late-stage AMD were not diminished when adjusting
for ever smoking (OR per SD increase in mLRRY: 0.854
[95% CI: 0.762; 0.932]), current smoking status (OR per
SD increase in mLRRY: 0.805 [95% CI: 0.701; 0.922]) or
pack-years (OR per SD increase in mLRRY: 0.877 [95%
CI: 0.735; 1.044]). Similarly, the association of mLOY did
not decrease when adjusting for smoking status (data not
shown).
Discussion
Here, we report the association of mLOY with AMD risk,
particularly in individuals between 65 and 75 years of age.
We deﬁned mLOY with agnostic thresholds from the mean
and SD of the mLRRY values in controls, as previously
published thresholds of mLRRY (such as −0.4 [13] or
−0.15 [15]) resulted in fewer samples with mLOY than
expected in this age range. This observation can be
explained by the different genotyping chip architecture
used in this study, which included a large exonic part to
capture the variation of rare variants. However, our deﬁ-
nition of mLOY based on one SD from the mean resulted
in a similar fraction of mLOY in controls as expected in
the respective age groups.
In line with independent results reported elsewhere [12,
13, 15], we also found that mLOY increased signiﬁcantly
with age in our study. Since age is the major risk factor for
AMD, we adjusted the analysis by age, ensuring that the
observed association is not driven by the increased age of
our AMD samples compared to controls.
Previously, the strongest genetic associations for AMD
were observed in or near genes of the complement system
[9] and an increased complement activation has been shown
to play a major role in AMD [11, 24, 25]. Enhanced and
prolonged complement activity and thus immune activation
might accelerate loss of Y chromosome and could be an
important confounder in our analysis. However, the
observed association of mLOY with AMD was independent
of known AMD risk variants, demonstrated by adjusting the
analysis for an AMD GRS, which revealed no inﬂuence on
the observed association. Of note, genome-wide association
studies aiming to uncover the genetic basis of mLOY have
not reported any associated loci harbouring complement
genes [20].
We observed that the association of mLOY with AMD is
reduced in individuals over 75 years of age. This is in full
agreement with a similar effect observed in the association
of mLOY with Alzheimer disease [13], with decreased
hazard ratios reported for older compared to younger indi-
viduals. It is known that in AMD genetic effects can be
modulated by age [5, 7, 23]. It has been hypothesised that
younger diseased individuals require more disease asso-
ciated variants to explain the early onset of disease
pathology. Similarly, mLOY at younger age may suggest an
increased impairment and senescence of the immune system
[12–14, 16, 17, 26], a process that is assumed to play a role
in AMD and other immune related diseases [27, 28] as well
as cancer [29, 30].
Taken together, we report a genome-wide signiﬁcant
association of mLOY with late-stage AMD independent of
known and potential confounders. The mLOY marginally
improved the AUC of the logistic regression model from
0.824 (GRS+ smoking+ age) to 0.827, which is consistent
with the degree of added risk from other known, low
penetrance genetic factors.
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